依帕司他对早期糖尿病肾病患者尿N-乙酰-β-D氨基葡萄糖苷酶与β2微球蛋白水平的影响

目的 观察依帕司他对早期糖尿病肾病患者尿N-乙酰-β-D氨基葡萄糖苷酶(NAG)及β2微球蛋白(β2-MG)水平的影响,评价其对肾小管损伤的疗效.方法 将60例早期糖尿病肾病患者完全随机分为治疗组及对照组,各30例.对照组常规饮食控制、口服降糖药或胰岛素处理,治疗组在此基础上加用依帕司他50 mg,3次/d,治疗前和治疗12周后应用终点比色法测定尿NAG,免疫透射比浊法测β2-MG,苦味酸法测定尿Cr的变化.对2组各项检测结果进行对比与分析.结果 2组治疗前后差异无统计学意义(P>0.05).治疗组患者治疗12周后较治疗前尿NAG/Cr、β2-MG/Cr、mALB/Cr均明显降低,分别为(2.0B±0.79)U/mmol比(3.69±1.35)U/mmol、(0.098±0.070)ms/nunol比(0.179±0.101)mg/mmol、(6.00±2.20)mg/mmol比(7.93±2.01)mg/mmol,差异有统计学意义(P<0.05).结论 依帕司他可明显降低早期糖尿病肾病患者尿NAG及β2-MG水平,提示其能早期干预肾小管损伤,保护肾脏.

Abstract：

Objective To investigate the effect of epalrestat on urinary N-aeetyl-β-Glucosaminidase(NAG)and β2-Micmglobulin(β2-MG)excretion in patients at early stage of diabetic nephropathies.Methods Sixty patients were divided randomly into two groups;the control group and the treatment group were both treated witll dietary control and oral hypoglycemic drugs or insulin,meanwhile,the treatment group were treated with epalrestat 50 mg three times a day.Results There were no significant difference between control group and treatment group(P>0.05).Urinary NAG/Cr,β2-MG/Cr and mALB/Cr were decreased significantly in epalrestat treatment group after 12 weeks,which were(2.03±0.79)U/mmol vs (3.69±1.35)U/mmol,(0.098±0.070)mg/mmol vs(0.179±0.101)mg/mmol,(6.00±2.20)mg/mmol vs (7.93±2.01)mg/mmol(P<0.05).Condusion Epalrestat can decrease the levels of urinary NAG and β2-MG significantly,which showes that epalrestat can alleviate renal tubular injury.